Liver X receptors LXRα and LXRβ are attractive drug targets from the nuclear receptor family. As they have a critical role in cholesterol metabolism and (reverse) transport and regulating innate immunity, they have been explored as promising targets in atherosclerosis, Alzheimer's disease, atopic dermatitis, and psoriasis. LXR has recently been demonstrated to be an effective regulator of the immune system in cancer patients by reducing the immunosuppressive myeloid-derived suppressor cell population and boosting the T-lymphocytes, which-in turn-leads to a pronounced anti-tumor response.
Lead Pharma has identified a proprietary series of selective small molecule LXR agonists, which exhibit superior efficacy in biochemical, cell-based and functional assays (ApoE secretion by immune cells) compared to competitor LXR agonists. The properties of our compounds offer a unique opportunity to develop best-in-class LXR agonists.
This project is currently in lead identification.